Sodium-dependent phosphate cotransporter type IIb (NaPi-IIb) (NaPi-IIb)

“Intestinal phosphate” refers to the absorption of inorganic phosphate ions in the small intestine via two principal mechanisms: a saturable, active transcellular pathway mediated primarily by the sodium-dependent phosphate cotransporter type IIb (NaPi-IIb/Npt2b), and a passive, paracellular pathway across tight junctions. NaPi-IIb functions as the major protein responsible for sodium-dependent transcellular phosphate uptake, regulated by hormones and dietary factors, and is highly expressed in intestinal epithelial cells. Paracellular phosphate transport is driven by electrochemical gradients and occurs via tight junction complexes, but specific protein identity for this pathway is currently unknown. Dysregulation of intestinal phosphate absorption plays a central role in the development of hyperphosphatemia in chronic kidney disease, making NaPi-IIb a potential therapeutic target. However, current evidence indicates that, in humans, the paracellular pathway predominates, and direct NaPi-IIb inhibitors have shown limited clinical efficacy[2][3][4][5].

Other names

Npt2bSLC34A2NaPi2bsodium-phosphate cotransporter family

Inhibitors block active phosphate transport by NaPi-IIb, reducing intestinal phosphate uptake, theoretically lowering serum phosphate concentrations in hyperphosphatemia. Phosphate binders act by binding dietary phosphate in the intestinal lumen, making it unavailable for absorption.